Gynecology

FRIDAY, NOVEMBER 22

08:30-10:00 HPV
 Hall C
Capsule As the cervical cancer elimination campaign takes shape, several initiatives are being considered in practical contexts. The session will explore some of them and specifically the role of the gynecologists
Chairperson Xavier Bosch, Spain
Panelists Mario Poljak, Slovenia
Maaike Bleeker, Netherlands
Pier Luigi Lopalco, Italy
Kevin Pollock, UK
  • General frame on cervical cancer elimination
  • Female HPV vaccine acceptance. Vaccination achievements
  • Vaccination crisis
  • Safety of the vaccines and the Cochrane dispute
  • Male vaccination. Expected penetrance and impact
  • Vaccinating women in screening ages (25-45+)
  • Transition to HPV primary screening in Europe
  • Self-sampling initiatives in Europe and in developing countries
  • HPV testing technology. Validation of tests
  • Questions from the  audience
10:20-11:40 INDUTRY SUPPORTED SESSION
 Hall C
12:10-13:40 VULVO-VAGINAL ATROPHY / GSM
 Hall C
Chairpersons Santiago Palacios, Spain
Alessandra Graziottin, Italy
12:10-12:55 Debate: Do we need RCTs for laser in VVA/GSM or are observational data enough?
For RCTS: Santiago Palacios, Spain
For observational/registry data: Marco Gambacciani, Italy
12:55-13:15 Can lasers reduce overactive bladder symptoms?
Zdenko Vizintin, Slovenia
13:15-13:40 VVA – Do we need to change nomenclature to GSM?
Bari Kaplan, Israel
14:30-16:30 BREAST CANCER
 Hall C
Chairpersons Herjan Coelingh Bennink, Netherlands
Nicholas Panay, UK
14:30-14:45 Does the choice of progestin matter for breast cancer risk?
14:45-15:00 Can HRT be individualized to reduce the incidence of breast cancer?
Mark Brincat, Malta
15:00-15:15 Prescribing what? Hormones? Contraception? MHT?
Anne Gompel, France
15:15-16:00 Debate: Does HRT increase the risk of breast cancer?
Yes: Serge Rozenberg, Belgium
No: Mark Brincat, Malta
16:00-16:30 Special Countercurrent lecture:
Gender, breast cancer and steroid hormones
Herjan Coelingh Bennink, Netherlands

SATURDAY, NOVEMBER 23

08:30-10:00 RISK FACTORS IN MENOPAUSE
 Hall C
Chairpersons Nicholas Panay, UK
Christian Egarter, Austria
08:30-09:00 Is there an increased CVD risk in PCOS women?
Roger A. Lobo, USA
09:00-09:30 Does anti-Müllerian hormone predict menopause in the general population? Results of a prospective ongoing cohort study
Joop Laven, Netherlands
09:30-10:00 Cardiovascular impact of progestins in women
Christian Egarter, Austria
10:20-11:50 UTERINE ANOMALIES; GYNE-ONCOLOGY
 Hall C
Capsule Counselling on protection of fertility became a standard of care
Chairpersons Ludwig Kiesel, Germany
Alessandra Graziottin, Italy
  UTERINE ANOMALIES
10:20-10:45 Symmetric and non-symmetric uterine anomalies
Leila Adamyan, Russia
10:45-11:05 Counseling young women with uterovaginal anomalies
George Creatsas, Greece
  GYNE-ONCOLOGY
11:05-11:30 Protecting reproductive potential in (gynecological) cervical cancer
Pierluigi Benedetti Panici, Italy
11:30-11:50 Protecting reproductive potential in ovarian cancer
Catherine Uzan, France
12:10-13:40 ADVANCES IN HORMONAL AND NON-HORMONAL RESEARCH
 Hall C
Chairperson Mark Brincat, Malta
George Creatsas, Greece
12:10-12:30 New progestogens / SPRMS: What are the possibilities?
12:30-12:55 New SERMS / TSECS: Can they be an HRT substitute?
Santiago Palacios, Spain
12:55-13:15 Targeting HRT:  From indication to personalization
Marco Gambacciani, Italy
13:15-13:40 Use of fetal estrogens for HRT: Are there benefits?
Herjan Coelingh Bennink, Netherlands
14:30-16:30 PREVENTION OF MENOPAUSAL SYMPTOMS
 Hall C
Chairpersons Santiago Palacios, Spain
Serge Rozenberg, Belgium
14:30-14:55 Should we use HRT for “prevention” in postmenopausal women
Roger A. Lobo, USA
14:55-15:15 How to overcome hormone resistance in women with breast cancer?
Ludwig Kiesel, Germany
15:15-16:00 Debate: Should androgens be routinely offered to optimize quality of life in menopause?
For:  Alessandra Graziottin, Italy
Against: Lydia Marie-Scemama, France
16:00-16:30 Special Countercurrent lecture:
Androgens: The need for a new consensus?
Nicholas Panay, UK
16:50-18:20 PERIMENOPAUSAL CONTRACEPTION
 Hall C
Chairperson Mark Brincat, Malta
16:50-17:10 Perimenopausal contraception: What are the current options?
Christian Egarter, Austria
17:10-17:35 What are the future contraceptive possibilities?
Phillipe Bouchard, France
17:35-17:55 Minimizing cardiovascular risks of perimenopausal contraception
Lydia Marie-Scemama, France
17:55-18:20 Optimizing psychosexual health with perimenopausal contraception
Alessandra Graziottin, Italy